Literature DB >> 17110063

Nanoparticles--a historical perspective.

Jörg Kreuter1.   

Abstract

The historical development of nanoparticles starting with Paul Ehrlich and then first attempts by Ursula Scheffel and colleagues and the extensive work by the group of Professor Peter Speiser at the ETH Zürich in the late 1960s and early 1970s are described from a personal point of view. Special attention is given to the years between 1970 and the early 1980s. Further developments resulting from this work are also followed, and focus is placed on especially interesting improvements such as nanoparticles for the delivery of drugs across the blood-brain barrier (BBB) and PEGylated nanoparticles with a prolonged blood circulation time.

Mesh:

Year:  2006        PMID: 17110063     DOI: 10.1016/j.ijpharm.2006.10.021

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  63 in total

Review 1.  Strategies in the design of nanoparticles for therapeutic applications.

Authors:  Robby A Petros; Joseph M DeSimone
Journal:  Nat Rev Drug Discov       Date:  2010-07-09       Impact factor: 84.694

2.  Design of Nanoparticle-Based Carriers for Targeted Drug Delivery.

Authors:  Xiaojiao Yu; Ian Trase; Muqing Ren; Kayla Duval; Xing Guo; Zi Chen
Journal:  J Nanomater       Date:  2016       Impact factor: 2.986

Review 3.  Oligonucleotide-based theranostic nanoparticles in cancer therapy.

Authors:  Reza Shahbazi; Bulent Ozpolat; Kezban Ulubayram
Journal:  Nanomedicine (Lond)       Date:  2016-04-22       Impact factor: 5.307

4.  Towards scale-up and regulatory shelf-stability testing of curcumin encapsulated polyester nanoparticles.

Authors:  Charitra N Grama; Vinod P Venkatpurwar; Dimitrios A Lamprou; M N V Ravi Kumar
Journal:  Drug Deliv Transl Res       Date:  2013-06       Impact factor: 4.617

Review 5.  Protein based therapeutic delivery agents: Contemporary developments and challenges.

Authors:  Liming Yin; Carlo Yuvienco; Jin Kim Montclare
Journal:  Biomaterials       Date:  2017-04-21       Impact factor: 12.479

Review 6.  Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.

Authors:  David Howard; Jetzabel Garcia-Parra; Gareth D Healey; Cynthia Amakiri; Lavinia Margarit; Lewis W Francis; Deyarina Gonzalez; R Steven Conlan
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

7.  Cytotoxicity of subtoxic AgNP in human hepatoma cell line (HepG2) after long-term exposure.

Authors:  Azin Nowrouzi; Khadijeh Meghrazi; Taghi Golmohammadi; Abolfazl Golestani; Shahin Ahmadian; Mahshid Shafiezadeh; Zahra Shajary; Shahnaz Khaghani; Azita N Amiri
Journal:  Iran Biomed J       Date:  2010 Jan-Apr

8.  Evolution and Clinical Translation of Drug Delivery Nanomaterials.

Authors:  Shabir Hassan; Gyan Prakash; Aycabal Ozturk; Saghi Saghazadeh; Mohammad Farhan Sohail; Jungmok Seo; Mehmet Dockmeci; Yu Shrike Zhang; Ali Khademhosseini
Journal:  Nano Today       Date:  2017-08-02       Impact factor: 20.722

Review 9.  Theranostic Nanoparticles for Tracking and Monitoring Disease State.

Authors:  Cristina Zavaleta; Dean Ho; Eun Ji Chung
Journal:  SLAS Technol       Date:  2017-11-08       Impact factor: 3.047

Review 10.  Nanoparticles and the brain: cause for concern?.

Authors:  Günter Oberdörster; Alison Elder; Amber Rinderknecht
Journal:  J Nanosci Nanotechnol       Date:  2009-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.